Skip to main content
Clinical Trials/JPRN-jRCT2080221558
JPRN-jRCT2080221558
Unknown
Phase 1

A phase I study of E7050 in subjects with solid tumors

Eisai Co., Ltd.0 sites33 target enrollmentSeptember 2, 2011

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
solid tumor, gastric cancer
Sponsor
Eisai Co., Ltd.
Enrollment
33
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 2, 2011
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Aged from 20 to less than 75 years old at the time of obtaining informed consent.
  • 2\. Histological or cytological diagnosis of solid tumors.
  • 3\. Subjects who have progressed after treatment with approved therapies or for whom there are no standard effective therapies available.
  • 4\. Adequate organ function.
  • 5\. Subjects who have no carryover of effect from prior therapy or no adverse drug reactions (excluding alopecia) that may affect the safety evaluation of the investigational drug.
  • 6\. Performance Status (PS) 0\-1 established by Eastern Cooperative Oncology Group (ECOG).
  • 7\. Expected to survive for 3 months or longer after starting administration of the investigational drug.

Exclusion Criteria

  • 1\. Females who are pregnant or breast feeding.
  • 2\. Brain metastases with clinical symptoms or which requires treatment.
  • 3\. Serious complications or disease history.
  • 4\. Subjects who cannot take oral medication.
  • 5\. Using antiplatelet/anticoagulant drugs.
  • 6\. Continuous using of drugs or foods that strongly inhibit or induce CYP3A4/5 or CYP2D6 during the study period.
  • 7\. Scheduled for surgery during the study period.
  • 8\. Known to be HIV, HBV or HCV positive.
  • 9\. Suffering from psychotic disorder(s) and/or unstable recurrent affective disorder(s) evident by use of anti\-psychotics or have had a suicide attempt(s) within approximately the last 2 years.
  • 10\. History of drug or alcohol dependency or abuse within 2 years.

Outcomes

Primary Outcomes

Not specified

Similar Trials